They’re not folks that should be on mailer, right, our average box has over seven drugs, and our average member has over 10 drugs and enrollments. And they are expressing extreme concern around taking those drugs, drugs as prescribed. That one through five drugs is really what we believe is the space for mail order. And we’re very supportive of the carriers actually, one of our partners, we’re their largest kind of referral source, or we do an opt-in since they have the ability to call the consumers on behalf of their mail-order pharmacy, and we’re the most successful shop doing that, while building this business. So we don’t really see it as friction, we see it as an opportunity to continue that partnership beyond just the MA plan.
Tim Danker: Yes, I think it’s really well said what Bob mentioned. We feel that we are very aligned with all participants in the value chain, a clearly a very different solution and high adherence solution, one that can help the consumer lead a healthier, happier life. They can help with through that adherence, then cost curves. And I think all the feedback that we’ve got from the broader ecosystem has been very positive.
Ben Hendrix: Great, thanks. Shifting gears again. Just real quick, I appreciate the comment on the P&C hard market cycle, any thoughts or any forecasts of kind of when we – it feels like we may be hitting towards an inflection point but any thoughts on kind of when we see material change in that space?
Tim Danker: Yes, we’ve certainly as we noted, last quarter, the P&C market have certainly had a hard market. I don’t know that we have any prognostication exactly when that makes often, there are some signs of that but also some carriers that are better resetting that right in terms of their underwriting specific to our brokerage, the business continues to perform quite well. It’s a good – obviously very strong value proposition but also is helping create meaningful cash flow for the customer or for the company. And we feel like even some of the activity that we’ve seen in terms of close rates and our ability to help convert customers through re-shopping, we’re having good progress on that. So more to come on that Ben.
Ben Hendrix: Great, thanks. My last question, I appreciate the commentary on the 1Q volume mix typically that you see, I was just wondering if there’s any EBITDA cadence thoughts you could offer at this point in the fiscal year? Thanks.
Tim Danker: Ryan?
Ryan Clement: Yes, I think as we shared on our last earnings call and the guide, we do are expecting that the EBITDA cadence and overall distribution by quarter for the various business segments will largely follow what we’ve historically recognized. The one deviation from that being the healthcare services business, which we’re projecting EBITDA margins in the low single digits, obviously entering the year in one slot and actually had a materially higher margin rate as we continue to grow and scale that business.
Ben Hendrix: Great. Thanks a lot, guys.
Tim Danker: Thank you, Ben.
Operator: Thank you. We currently have no further questions. Therefore, I will hand back to Tim Danker for any closing remarks.
Tim Danker: Well, thank you again for joining us as we enter the busy season for our Medicare Advantage and Healthcare Services segment. To say it again, we have a lot of confidence in our strategy, conviction grows with each quarter that’s like what drives strong profitability and cash flow. We certainly believe fiscal ’24 will be more of the same and with the scale of our Healthcare Services segment will drive even more operating leverage for the company. So we thank you again, and look forward to speaking next quarter. Everyone have a good evening.
Operator: This concludes today’s conference call. Thank you all for joining. You may now disconnect your lines.
